• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Tuberculosis treatment

Tuberculosis treatment



TB treatment principles by Daniel schwartz - LSMU

TB treatment principles by Daniel schwartz - LSMU



Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    Tuberculosis treatment Tuberculosis treatment Presentation Transcript

    • Tuberculosis treatment: general principles and approach Lecturer: Ph.D M.G.Dolynska
    • Historical background
      • Supposed incurable until XX century
      • First approach – sanatorium movement
      • First pathogenically based attempt –artificial pnemothorax (Forlanini, 1882)
      • Streptomycin discovery (Zelman Waksman, 1943)
    • The AIMS of treatment of tuberculosis are:
      • to cure the patient of TB;
      • to prevent death from active TB or its late effects;
      • to prevent relapse of TB;
      • to decrease transmission of TB to others;
      • to prevent the development of acquired drug resistance.
    • DOTS ( Directly observed treatment short course ), Karel Styblo, 1972
      • The organizational principles of the DOTS are:
      • availability of a decentralized diagnostic and treatment network based on existing health facilities;
      • good programme management based on accountability and supervision of health care workers;
      • an evaluation system of case-finding and cohort analysis of treatment outcomes.
    • The five elements of the expanded DOTS framework are:
      • 1.Sustained political commitment to increase human and financial resources and make TB control a nationwide priority integral to the national health system.
      • 2. Access to quality-assured TB sputum microscopy for case detection among persons presenting with, or found through screening to have, symptoms of TB (most importantly, prolonged cough).
      • 3. Standardized short-course chemotherapy for all cases of TB under proper case management conditions, including direct observation of treatment.
      • 4. Uninterrupted supply of quality-assured drugs with reliable drug procurement and distribution systems.
      • 5. Recording and reporting system enabling outcome assessment of all patients and assessment of overall programme performance.
    • Dosage and abbreviation of essential antituberculosis drugs 30 (20-35) 15 (15-20) Ethambutol (E) 15 (12-18) 15 (12-18) Streptomycin (S) 35 (30-40) 25 (20-30) Pyrasinamide (Z) 10 (8-12) 10 (8-12) Rifampicin (R) 10 (8-12) 5 (4-6) Isoniasid (H) 3 times weekly Daily Recommended dosage (dose range) in md/kg Drug (abbreviation)
    • Basical treatment regimens Optional 5 (HRE) 3 Optional 2(HRZES) 3 /1HRZE 3 Preferred 5 HRE VI Preferred 2 HRZES / 1 HRZE VI Previously treated sputum smearpositive PTB: - relapse; - treatment after default II Optional 4 (HR)3 or 6 HE V Optional or 2 (HRZE) 3 or 2 HRZE IV Preferred 4 HR 4 (HR)3 Preferred 2 HRZE I New smear-positive patients; new smear-negative PTB with extensive parenchymal involvement; concomitant HIV disease or severe forms of extrapulmonary TB I Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
    • Basical treatment regimens (continued) WHO/CDS/TB/2003.313 Treatment of tuberculosis:guidelines for national programmes, third edition. Revision approved by STAG, June 2004 Specially designed standardized or individualized regimens Chronic (still sputum-positive after supervised re-treatment); proven or suspected MDR TB cases. IV Optional 4 (HR)3 or 6 HE Optional 2 (HRZE)3 Preferred 4 HR Preferred 2 HRZE VIII New smear-negative PTB (other than in category I) and less severe forms of extra-pulmonary TB III Continual phase Initial phase Treatment regimen I TB patients Diagnostic category
    • Criticism concern with the DOTS strategy
      • Clinical
      • Lack of smear-negative case detecting
      • Lack of case monitoring
      • Ethical
      • Treatment refusal for certain categories (especially chronic and smear-negative)
      • Epidemiological
      • Potential hazard of untreated treated in improper way patients
    • Expanded treatment conception
      • Appropriate antibacterial treatment.
      • Hygienic and dietary regimen.
      • Pathogenetic measures:
      • desintoxication
      • hepatotropic therapy
      • tissue stimulation
      • Collapsotherapy
      • Surgical treatment.
      • For the future, the top priority remains to a dminister standardized short
      • course chemotherapy regimens to all smear positive cases (new and
      • retreatment cases). This priority requires the maximum of effort, time,
      • drugs and money in a national tuberculosis programme, without
      • diverting funds and resources to smear negative and/or chronic cases.
    • Drug resistance
      • Primary
      • Concern with drug-resistant strains inoculation
      • Asquired
      • Produced by ineffective treatment
    • Drug resistance
      • Simple drug resistance– resistance to more than two first line drugs including isoniasid or rifampicin
      • Multidrug-resistance (MDR) – resistance to more than two first line drugs including both isoniasid and rifampicin
    • Main resistance types
      • XDR
      Resistance mono MDR poly
    • MDR-TB prevalence among new cases and countries in which at least one XDR-TB case has been reported At the end of 2006 year XDR-TB has been detected in 17 countries
    • Extensively drug resistance (XDR) – main definitions
      • Firstly has been proposed by US Centers of Disease Control and Prevention (CDC) in March, 2006: the disease, caused by MBT, resistant to HR (MDR-TB) and to at least 3 from six classes of antituberculosis second-line drugs (aminoglycosides, polypeptide, fluoquinolones, thyamides, cyclocerine, PAS)
      • But on WHO meeting devoted to XDR problem (meeting of the WHO XDR-TB Task Force ), on October, 10-11 , 2006 difinition has been changed : the disease, caused by MBT, resistant to HR (MDR-TB) and to at least some fluoquinolones and one from 3 injectional antituberculosis drugs : cyclopentin , kanamycin, amicacin .
    • Second line drugs
      • Less effective
      • More toxic
      • Much more expensive
    • Classes of second-line antituberculosis drugs
      • a Aminoglycosides
      • When resistance to streptomycin is proved or highly suspected, one of
      • the other aminoglycosides can be used as a bactericidal agent against
      • actively multiplying organisms:
      • • kanamycin , the least expensive, but largely used for indications other
      • than tuberculosis in some countries.
      • • amikacin , as active as kanamycin and better tolerated, but much more
      • expensive.
      • • capreomycin ,2 very expensive but very useful in cases with tubercle
      • bacilli resistant to streptomycin, kanamycin and amikacin.
    • Classes of second-line antituberculosis drugs
      • b Thioamides
      • Ethionamide or prothionamide are 2 different presentations of the
      • same active substance, with bactericidal activity. Prothionamide may be
      • better tolerated than ethionamide in some populations.
      • c Fluoroquinolones
      • Ofloxacin and ciprofloxacin are two different drugs, but with complete
      • cross-resistance within the group. These drugs have a low bactericidal
      • activity, and are useful in association with other drugs. The
      • pharmacokinetics of ofloxacin are better than the pharmokinetics of
      • ciprofloxacin. Sparfloxacin should be avoided because of severe
      • cutaneous side effects (photo-sensitisation). Norfloxacin should not be
      • used, because it does not give adequate serum levels .
    • Classes of second-line antituberculosis drugs
      • d Cycloserine (or terizidone)
      • This is the same bacteriostatic agent, with 2 different formulations. It has
      • no cross-resistance with other antituberculosis agents. It might be
      • valuable to prevent resistance to other active drugs, but its use is limited
      • by its high toxicity.
    • Classes of second-line antituberculosis drugs
      • Para-aminosalicylic acid (PAS)
      • This is a bacteriostatic agent, valuable for preventing resistance to
      • isoniazid and streptomycin in the past and to other bactericidal drugs today.
      • f Others
      • Other drugs, sometimes mentioned as second line antituberculosis
      • drugs, have no place in the treatment of MDR tuberculosis:
      • • rifampicin derivatives, like rifabutin (21), cannot be used since there is a lmost complete cross-resistance between rifabutin and rifampicin
      • (especially when there is acquired resistance to rifampicin);
      • • clofazimine has some activity against Mycobacterium leprae and
      • Mycobacterium ulcerans, but no activity against Mycobacterium
      • tuberculosis.
    • Acceptable regimen for the treatment of MDR Tuberculosis
      • It must be made clear to the patient and staff that meticulously taking the prescribed reserve regimen is all that stands between the patient and death.
    • Recovery criteria
      • Clinical symptoms disappearing
      • Morphological changes resolving
      • Sputum conversion (by all available tests)
    • TB and HIV treatment sequence